Your Shopping Cart Is Empty
| Report Code: A06106 | Mar 2020 | Pages: 194 | ||
| Tables: 85 | Charts: 57 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Influenza Treatment Market
Request Now !The global influenza treatment market size accounted for $861.50 million in 2018, and is expected to reach $1,225.20 million by 2026, registering a CAGR of 4.5% from 2019 to 2026.
Influenza is commonly known as flu and is a contagious respiratory infection, which is caused by influenza viruses. Furthermore, the virus is classified into Type A, B, C, and D. The most common types of influenza virus responsible for seasonal flu each year are Type A and B. Moreover, these viruses attack respiratory system of an individual and are transmitted to other individual by direct contact or inhalation of virus laden aerosols. The major symptoms of the disease include sore throat, fatigue, muscle ache, vomiting, and diarrhea. In addition, it can worsen long-term medical conditions like congestive heart failure, asthma, or diabetes which, in turn, can lead to serious complications. Therefore, influenza infections are treated in time using various types of anti-viral drugs such as Peramivir and Zanamivir.
The major factor that contribute to the growth of the influenza treatment market include rise in incidences of influenza across the globe. Furthermore, other factors such as surge in healthcare expenditure, and rise in R&D investments related to anti-viral drugs further boost the influenza treatment market growth. For instance, in 2018, F. Hoffmann-La Roche AG launched Xofluza (Baloxavir Marboxil) for the treatment of influenza. Furthermore, Xofluza is the first new flu medicine with a novel proposed mechanism of action. Therefore, this leads to availability of better treatment option for the patients. However, adoption of influenza vaccines hampers the growth of the influenza treatment market. Conversely, high growth potential exhibited by developing economies such as India and China having a large population base and notable epidemiology of influenza infection is expected to offer lucrative opportunities for the market during the forecast period.
The influenza treatment market size is studied on the basis of product type, distribution channel, and region to provide a detailed assessment. On the basis of product type, it is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. By distribution channel, it is bifurcated into retail pharmacy, hospital pharmacy, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
Segment Review
By product, the market is classified into is segmented into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others. The others segment acquired the largest share of the influenza treatment market in 2018. Furthermore, the segment is also anticipated to exhibit fastest growth during the forecast period. The growth of this segment is attributable to surge in prevalence of influenza virus infection across the globe. Furthermore, rise in awareness related to early diagnosis of the infection for better treatment is another major reason that contributes to the growth of the market.
By distribution channel, the influenza treatment market is divided into retail pharmacy, hospital pharmacy, and others. The retail pharmacy segment occupied the largest market share in 2018, owing to factors such as rise in number of retail pharmacies across the globe. In addition, other factors such as rise in awareness related to use of influenza drugs is another major factor that contributes to the growth of the market. The other factors which boost the growth of the market include surge in the number of retail pharmacies across the globe which lead to easy availability of influenza drugs. On the contrary, the others segment is expected to witness the fastest growth rate during the forecast period due to surge in use of internet across the globe, which allows consumers to buy drugs online.
By region, North America accounted for the major influenza treatment market share in 2018, and is expected to continue this trend, owing to easy availability of influenza treatment. Moreover, surge in incidences of influenza infection is another major reason that contributes to the growth of this market. Moreover, surge in the awareness towards early diagnosis of the medical condition for better treatment is another major factor that contributes to the growth of the market. However, Asia-Pacific is estimated to register the fastest growth rate during the forecast period, owing to increase in awareness regarding the use of influenza drugs for the treatment of infection. Moreover, increase in healthcare expenditure and surge in awards related to use of influenza treatment is another major factor that boosts the growth of the influenza treatment market. In addition, presence of key players in these regions also fuels the growth of the influenza treatment in Asia-Pacific. In addition, the constantly evolving life science industry in Asia-Pacific drives the growth of the market in developing economies such as India, China, and Malaysia.
The global influenza treatment market is highly competitive and prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include AstraZeneca Plc, BioCryst Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Mylan N.V, Natco Pharma Limited, Novartis AG, Sanofi, and Teva Pharmaceutical Industries Limited.
Influenza Treatment Market Report Highlights
| Aspects | Details |
|---|---|
| By Product Type |
|
| By Distribution Channel |
|
| By Region |
|
| Key Market Players | F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, MYLAN N.V, NATCO Pharma Limited, BioCryst Pharmaceuticals, Inc., TEVA PHARMACEUTICAL INDUSTRIES LIMITED, Daiichi Sankyo Company, Limited, SANOFI, AstraZeneca Plc, NOVARTIS AG |
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping influenza treatment industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in incidences of influenza across the globe
3.4.1.2. Increase in healthcare expenditure worldwide
3.4.1.3. Rise in R&D investments for discovery of new drugs
3.4.2. Restraint
3.4.2.1. Presence of substitutes for the treatment of influenza
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analysis
CHAPTER 4: INFLUENZA TREATMENT MARKET, BY PRODUCT TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Peramivir
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Zanamivir
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Oseltamivir Phosphate
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Baloxavir Marboxil
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Other products
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
CHAPTER 5: INFLUENZA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Retail Pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Hospital Pharmacy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
CHAPTER 6: INFLUENZA TREATMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by product type
6.2.2.1.2. U.S. market size and forecast, by distribution channel
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by product type
6.2.2.2.2. Canada market size and forecast, by distribution channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by product type
6.2.2.3.2. Mexico market size and forecast, by distribution channel
6.2.3. North America market size and forecast, by product type
6.2.4. North America market size and forecast, by distribution channel
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by product type
6.3.2.1.2. Germany market size and forecast, by distribution channel
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by product type
6.3.2.2.2. France market size and forecast, by distribution channel
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by product type
6.3.2.3.2. UK market size and forecast, by distribution channel
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by product type
6.3.2.4.2. Italy market size and forecast, by distribution channel
6.3.2.5. Rest of Europe
6.3.2.5.1. Rest of Europe market size and forecast, by product type
6.3.2.5.2. Rest of Europe market size and forecast, by distribution channel
6.3.3. Europe market size and forecast, by product type
6.3.4. Europe market size and forecast, by distribution channel
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by product type
6.4.2.1.2. Japan market size and forecast, by distribution channel
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by product type
6.4.2.2.2. China market size and forecast, by distribution channel
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by product type
6.4.2.3.2. India market size and forecast, by distribution channel
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by product type
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by distribution channel
6.4.3. Asia-Pacific market size and forecast, by product type
6.4.4. Asia-Pacific market size and forecast, by distribution channel
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by product type
6.5.2.1.2. Brazil market size and forecast, by distribution channel
6.5.2.2. South Africa
6.5.2.2.1. South Africa market size and forecast, by product type
6.5.2.2.2. South Africa market size and forecast, by distribution channel
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia market size and forecast, by product type
6.5.2.3.2. Saudi Arabia market size and forecast, by distribution channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by product type
6.5.2.4.2. Rest of LAMEA market size and forecast, by distribution channel
6.5.3. LAMEA market size and forecast, by product type
6.5.4. LAMEA market size and forecast, by distribution channel
CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca Plc
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. BioCryst Pharmaceuticals, Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. Daiichi Sankyo Company, Limited
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. F. Hoffmann-La Roche AG
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. GlaxoSmithKline Plc
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. MYLAN N.V
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. NATCO Pharma Limited
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. NOVARTIS AG
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. SANOFI
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL INFLUENZA TREATMENT MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 02. PERAMIVIR INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. ZANAMIVIR INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. OSELTAMIVIR PHOSPHATE INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BALOXAVIR MARBOXIL INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. OTHER PRODUCTS INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. GLOBAL INFLUENZA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026 ($MILLION)
TABLE 08. RETAIL PHARMACY INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. HSOPITAL PHARMACY INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. OTHERS INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 12. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 13. U.S. INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 14. U.S. INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 15. CANADA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 16. CANADA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 17. MEXICO INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 18. MEXICO INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 19. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($MILLION)
TABLE 20. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 21. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 22. GERMANY INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 23. GERMANY INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 24. FRANCE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 25. FRANCE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 26. UK INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 27. UK INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 28. ITALY INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 29. ITALY INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 30. REST OF EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 31. REST OF EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 32. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($MILLION)
TABLE 33. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 34. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 35. JAPAN INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 36. JAPAN INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 37. CHINA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 38. CHINA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 39. INDIA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 40. INDIA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 41. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 42. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 43. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($MILLION)
TABLE 44. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 45. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 46. BRAZIL INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 47. BRAZIL INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 48. SOUTH AFRICA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 49. SOUTH AFRICA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 50. SAUDI ARABIA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 51. SAUDI ARABIA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 53. REST OF LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 54. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($MILLION)
TABLE 55. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 56. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 57. ASTRAZENECA: OPERATING SEGMENTS
TABLE 58. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 59. BIOCRYST: COMPANY SNAPSHOT
TABLE 60. BIOCRYST: OPERATING SEGMENTS
TABLE 61. BIOCRYST: PRODUCT PORTFOLIO
TABLE 62. DAIICHI-SANKYO: COMPANY SNAPSHOT
TABLE 63. DAIICHI-SANKYO: OPERATING SEGMENTS
TABLE 64. DAIICHI-SANKYO: PRODUCT PORTFOLIO
TABLE 65. ROCHE: COMPANY SNAPSHOT
TABLE 66. ROCHE: OPERATING SEGMENTS
TABLE 67. ROCHE: PRODUCT PORTFOLIO
TABLE 68. GSK: COMPANY SNAPSHOT
TABLE 69. GSK: OPERATING SEGMENTS
TABLE 70. GSK: PRODUCT PORTFOLIO
TABLE 71. MYLAN: COMPANY SNAPSHOT
TABLE 72. MYLAN: OPERATING SEGMENTS
TABLE 73. MYLAN: PRODUCT PORTFOLIO
TABLE 74. NATCO: SNAPSHOT
TABLE 75. NATCO PHARMA LIMITED: OPERATING SEGMENTS
TABLE 76. NATCO PHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 77. NOVARTIS: COMPANY SNAPSHOT
TABLE 78. NOVARTIS AG.: OPERATING SEGMENTS
TABLE 79. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 80. SANOFI: COMPANY SNAPSHOT
TABLE 81. SANOFI: PRODUCT SEGMENTS
TABLE 82. SANOFI: PRODUCT PORTFOLIO
TABLE 83. TEVA: COMPANY SNAPSHOT
TABLE 84. TEVA: OPERATING SEGMENTS
TABLE 85. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO:
LIST OF FIGURES
FIGURE 01. GLOBAL INFLUENZA TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, INFLUENZA TREATMENT MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PERAMIVIR INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ZANAMIVIR INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OSELTAMIVIR PHOSPHATE INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BALOXAVIR MARBOXIL INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OTHER PRODUCTS INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OTHERS INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. U.S. INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 19. CANADA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 20. MEXICO INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 21. GERMANY INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 22. FRANCE INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 23. UK INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 24. ITALY INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 25. REST OF EUROPE INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 26. JAPAN INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 27. CHINA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 28. INDIA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 29. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 30. BRAZIL INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 31. SOUTH AFRICA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 32. SAUDI ARABIA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 33. REST OF LAMEA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 34. ASTRAZENECA: NET SALES, 2017–2019 ($MILLION)
FIGURE 35. ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 36. BIOCRYST: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. DAIICHI-SANKYO: NET SALES, 2016–2018 ($MILLION)
FIGURE 38. DAIICHI-SANKYO: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 39. DAIICHI-SANKYO: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. ROCHE: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 42. ROCHE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 43. GSK: NET SALES, 2017–2018 ($MILLION)
FIGURE 44. GSK: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 45. GSK: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 46. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 47. MYLAN: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 48. MYLAN: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 49. NATCO: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. NOVARTIS: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 52. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 53. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 54. SANOFI: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 55. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 56. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 57. TEVA: REVENUE SHARE BY REGION, 2018 (%)
Influenza is defined as a viral infection which affects the respiratory system. The early symptoms of the disease include high fever, muscle pain, headache, and others. Furthermore, the infection is air-borne and is highly contagious. The treatment of the infection is achieved through administration of various anti-viral drugs such as Peramivir, Zanamivir, and Oseltamivir and others.
The utilization of influenza drugs has witnessed a significant growth, owing to surge in incidences of influenza across the globe. The other factors that propel the utilization of different influenza treatments include surge in healthcare expenditure and rise in R&D investments related to anti-viral drugs. Conversely, surge in adoption of influenza vaccines is a factor that restricts the growth of the market. However, high market potential due to rise in awareness related to availability and use of influenza treatment options offered by in developing economies is expected to present lucrative opportunities for the key players during the forecast period..
A. The total market value of influenza treatment market is $ 861.50 million in 2018.
A. The forcast period for influenza treatment market is 2019 to 2026
A. The market value of influenza treatment market in 2019 is $ 900.30 million.
A. The base year is 2018 in influenza treatment market
A. Top companies such as, AstraZeneca Plc, F. Hoffmann-La Roche AG., GlaxoSmithKline Plc, Mylan N.V, and Daiichi Sankyo Company, Limite held a high market position in 2018. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Other influenza treatments segment is the most influencing segment surge in the prevalence of the influenza virus infection across the globe. Furthermore, the surge in the awareness related to early diagnosis of the infection for better treatment is another major reason that contribute to the growth of the market.
A. The major factor that fuels the growth of the global influenza treatment market includes rise in R&D investments for discovery of new drug molecules. Therefore, this leads to availability of better treatment option for the patients.
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 5.6%. Presence of a large patient base coupled with surge in awareness relate to early diagnosis of the medical condition in drive growth of influenza treatment market.
A. Influenza treatments include all the anti-viral medications which are employed in the treatment of the influenza. Some of the influenza treatments available in the market include Peramivir, Zanamivir, Oseltamivir Phosphate and others
A. Influenza treatment exhibit different mechanism of action on influenza virus. For instance, drugs such as Zanamivir work on influenza by trapping the virus inside the infected cell which prevents the spreading of infection in the respiratory tract.
Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report